Skip to main content
OpenTrials
Completed

NCT Number: NCT03922945

A Phase IV Safety and Efficacy Study of VI-0521 in Adolescents With Obesity

This study is being conducted to assess weight loss efficacy, as determined by changes in body mass index (BMI), and safety of VI-0521 (Qsymia®) or placebo, taken for 56 weeks accompanied by a lifestyle modification program in obese adolescents age 12-16 years.

Completed

Looking for future studies?

Notify Me

Key information

Age range

12 year–16 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Intend Research, LLC

Norman, Oklahoma, 73069, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged ≥ 12 years and < 17 years;
  • BMI ≥ the 95th percentile, with documented history of failure to lose sufficient weight or failure to maintain weight loss in a lifestyle modification program;
  • If female, must be using adequate contraception, defined as double barrier methods, stable hormonal contraception plus single barrier method, tubal ligation, or abstinence.

Exclusion criteria

  • Type 1 diabetes;
  • Congenital heart disease; clinically significant ECG abnormality;
  • Clinically significant physical exam, vital signs, or laboratory abnormality; clinically significant hepatic or renal disease;
  • Estimated Glomerular Filtration Rate (GFR; Schwartz formula) < 60 mL/minute;
  • Clinically significant thyroid dysfunction as evidenced by signs, symptoms, or thyroid stimulating hormone (TSH) > 1.5 x Upper Limit of Normal;
  • Obesity of known genetic or endocrine origin;
  • History of bipolar disorder or psychosis, depression of moderate or greater severity, or presence or history of suicidal behavior or active suicidal ideation;
  • Recent weight instability, or prior bariatric surgery;
  • History of glaucoma or increased intraocular pressure;
  • Current smoker or smoking cessation within 3 months of screening;
  • Currently taking or plan on taking any of following medications during the study:
  • Anticonvulsants used for treatment of seizure disorder, including barbiturates, benzodiazepines, gamma-aminobutyric acid (GABA) analogues, hydantoins, phenyltriazines, succinimides, and other agents (valproic acid and its derivatives, carbamazepine and its derivatives, zonisamide, and felbamate);
  • Tricyclic antidepressants, monoamine oxidase inhibitors (MAOIs), lithium, levodopa, and dopamine receptor agonists;
  • Carbonic anhydrase inhibitors;
  • Insulin, Sulfonylureas (SFUs), glucagon-like peptide -1 (GLP-1) agonists, sodium glucose transporter-1 (SGLT-1), and SGLT-2 inhibitors;
  • Chronic systemic steroids (i.e. glucocorticoids, anabolic steroids) other than oral contraceptives;
  • Treatment for hyperactivity disorder; or
  • Over the counter, prescription medications, herbal agents and dietary supplements used with the intention to lose body weight.

Treatment and study plan

VI-0521 oral capsule

Drug

Phentermine/Topiramate

Other names: Qsymia, Phentermine and topiramate

Placebo oral capsule

Drug

Inactive drug

Lifestyle Modification

Behavioral

The lifestyle modification includes physical activity, behavior change, reduced calorie diet advice, and family support. This intervention is applied to all treatment groups.

Primary outcomes

  1. Mean % Change in Body Mass Index (BMI)

    Time frame: Baseline to Week 56

    Mean % change in BMI from Baseline to Week 56

Secondary outcomes

  1. Percentage of Subjects Achieving at Least 5% BMI Reduction at Week 56

    Time frame: Baseline to Week 56

  2. Percentage of Subjects Achieving at Least 10% BMI Reduction at Week 56

    Time frame: Baseline to Week 56

  3. Percentage of Subjects Achieving at Least 15% BMI Reduction at Week 56

    Time frame: Baseline to Week 56

  4. Change in Waist Circumference at Week 56

    Time frame: Baseline, Week 56

    Change in waist circumference from Baseline to Week 56

  5. Change in Whole Body Insulin Sensitivity Index (WBISI) (Matsuda) at Week 56

    Time frame: Baseline, Week 56

    Mean changes in glycemic parameters [Whole Body Insulin Sensitivity Index (WBISI) (Matsuda)] from baseline to Week 56. The Oral Glucose Tolerance Test (OGTT) were performed at Baseline and Week 56 using 75 g oral glucose load; blood samples were obtained at baseline and at 2 hours post glucose load for evaluation of both glucose and insulin levels. Insulin Sensitivity was measured by obtaining glucose and insulin levels in a fasting state and at 2 hours after administration of oral glucose load. Matsuda index = 10,000/SQRT [glucose concentration (mg/dL) (fasting)*insulin concentration (uIU/mL) (fasting)*glucose concentration (mg/dL) (2 hours after glucose load)*insulin concentration (uIU/mL) (2 hours after glucose load)], with higher numbers indicating better insulin sensitivity.

  6. Change in Fasting Insulin at Week 56

    Time frame: Baseline, Week 56

    Change in fasting insulin from Baseline to Week 56

  7. Percent Change in Triglycerides From Baseline to Week 56

    Time frame: Baseline, Week 56

  8. Percent Change in HDL-C From Baseline to Week 56

    Time frame: Baseline, Week 56

  9. Change From Baseline in Systolic Blood Pressure at Week 56

    Time frame: Baseline, Week 56

  10. Change From Baseline in Diastolic Blood Pressure at Week 56

    Time frame: Baseline, Week 56

Sponsors and collaborators

Lead sponsor

VIVUS LLC

Industry

Registry information

Official study title

A Phase IV, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Study to Determine the Safety and Efficacy of VI-0521 in Obese Adolescents

Important dates

Study start
2019
Primary completion
2021
Study completion
2021
First posted
Apr 22, 2019
Registry last updated
Sep 10, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.